Abstract
153 patients suffering from recurrent pathologies, i.e. viral infections (keratitis, keratouveitis, genital and labial herpes) uveitis, cystitis, and candidiasis were treated with in vitro produced transfer factor (TF) specific for HSV-1/2, CMV and Candida albicans. The cell-mediated immunity of seropositive patients to HSV-1/2 and/or CMV viruses was assessed using the leucocyte migration inhibition test (LMT) and lymphocyte stimulation test (LST) in presence of the corresponding antigens, and the frequency of positive tests before, during and after TF administration was studied. The data were stratified per type of test, antigen and the recipients' pathology, and statistically evaluated. For the LMT, a total of 960 tests were carried out for each antigen dilution, 3 different antigen dilutions were used per test. 240/960 tests (25.4%) were found positive during non-treatment or treatment with unspecific TF, whereas 147/346 tests (42.5%) were found positive when the antigen corresponding to the specificity of the TF administered to the patient was used (P < 0.001). When the data were stratified following pathology, a significant increased incidence of positive tests during specific treatment was also observed (0.0001 < P < 0.05...Continue Reading
References
Jan 1, 1977·Cellular Immunology·B H LittmanJ R David
Jan 1, 1979·Clinical Immunology and Immunopathology·M S Ascher, L A Andron
Jul 1, 1979·The Journal of Allergy and Clinical Immunology·G B WilsonH H Fudenberg
Sep 1, 1977·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·G PizzaF Corrado
Jun 1, 1976·British Journal of Cancer·G PizzaF Corrado
Nov 1, 1991·Clinical and Experimental Immunology·W E AulitzkyC Huber
Dec 1, 1990·Journal of the Neurological Sciences·J C Alvarez-CermeñoP Gonzalez-Porque
Jul 1, 1990·Acta Neurologica Scandinavica·J C Alvarez-CermeñoP Gonzalez-Porque
Jan 1, 1989·Annual Review of Pharmacology and Toxicology·H H Fudenberg, H H Fudenberg
Jan 13, 1989·Cell·J SchneckD H Margulies
Jul 1, 1986·Cellular Immunology·D VizaD A Davies
Apr 1, 1974·Proceedings of the National Academy of Sciences of the United States of America·M S AscherH S Lawrence
Feb 1, 1967·Acta Medica Scandinavica·M Soborg, G Bendixen
Aug 14, 1980·The New England Journal of Medicine·R W SteeleM M Vincent
Sep 15, 1984·International Journal of Cancer. Journal International Du Cancer·G PizzaF Corrado
Oct 1, 1982·Proceedings of the Society for Experimental Biology and Medicine·D V AblashiG Pizza
May 1, 1982·Clinical Immunology and Immunopathology·G B WilsonH H Fudenberg
Jan 1, 1994·Biotherapy·G PizzaD Viza
Mar 1, 1995·Immunology Today·F PuppoS Ferrone
Jul 1, 1994·Human Immunology·J InostrozaR Sorensen
Jul 1, 1994·Human Immunology·K K SaririanC Russo
Nov 1, 1994·Transgenic Research·C A PinkertL J Striker
Aug 1, 1994·Human Immunology·F PuppoS Ferrone
May 6, 1994·Cell·G Gafvelin, G von Heijne
Jan 1, 1996·Biotherapy·R MeduriD Viza
Jan 1, 1996·Biotherapy·G PizzaR Baricordi
Jan 1, 1996·Biotherapy·M MasiO R Baricordi
Jan 1, 1996·Biotherapy·C De VinciD Viza
Feb 1, 1955·The Journal of Clinical Investigation·H S LAWRENCE
Aug 1, 1949·Proceedings of the Society for Experimental Biology and Medicine·H S LAWRENCE
Citations
Oct 9, 2013·Journal of Pharmaceutical and Biomedical Analysis·Emilio Medina-RiveroSonia Mayra Pérez-Tapia
May 20, 2015·Journal of Immunology Research·Nohemí Salinas-JazmínSonia Mayra Pérez-Tapia
Jul 15, 2017·Journal of Immunotoxicology·Sandra AvilaSonia Mayra Pérez-Tapia
Aug 9, 2020·Journal of Personalized Medicine·Anderson O FerreiraEli C F Dijkers